Back to Scientific publications

B03-targeting-hla-h-or-hla-j-peptides-triple-negative-breast-cancer

B03-targeting-hla-h-or-hla-j-peptides-triple-negative-breast-cancer

Michel Salzet, Marie Duhamel


WO 2026/058015 A1
https://patents.google.com/patent/WO2026058015A1/en

Abstract

The application reports that the non-classical HLA proteins HLA-H and HLA-J are expressed at the surface of breast tumour cells, and in particular of triple-negative breast cancer cells, which makes the peptides they present candidate tumour-restricted targets.

It claims chimeric antigen receptors whose extracellular domain specifically recognises a surface peptide of HLA-H or HLA-J, the nucleic acids encoding them and the immune cells expressing them — preferentially furin-inhibited CAR macrophages — together with their therapeutic use in breast cancer.

Patent family

Publication numberOfficeKindPublished
WO 2026/058015 A1WIPOApplication2026-03-19
  • Priority date — 11 September 2024
  • Filing date — 11 September 2024
  • Status — Pending (PCT)
  • Applicants — Inserm, Université de Lille, CHU de Lille
  • Research axis — Immunotherapy & tumour targets

Context

This is the target side of the laboratory’s CAR macrophage programme: the therapeutic vector is covered by WO 2025/177014, this application covers the antigens it is directed against. HLA-H and HLA-J are non-classical class I HLA genes usually described as pseudogenes, so surface expression of the corresponding proteins on tumour cells is a substantial claim.

Abstract as published

The present results show for the first time that the HLA proteins HLA-H and HLA-J are specifically expressed at the surface of breast tumor cells (in particular Triple Negative Breast Cancer) and can therefore serve as specific targets for various immunotherapeutic agents, preferably CAR-expressing macrophages. The invention specifically proposes to use furin-inhibited CAR-macrophages targeting extracellular peptides of the HLA-H or HLA-J proteins for treating patients suffering from breast cancer, in particular from Triple Negative Breast Cancer.